Tirzepatide denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for Tirzepatide

Aetna requires prior authorization (PA) for tirzepatide, meaning the plan must approve coverage before the prescription is filled. A prior-auth-required denial at the pharmacy counter does not necessarily mean your request was reviewed and rejected — it often means a PA was never submitted or was submitted without sufficient supporting documentation. The distinction matters: if no PA was filed, the fix is to file one; if one was filed and denied, you are in the appeal process.

This is one of the most addressable coverage barriers for tirzepatide. The PA process exists to confirm that the prescription meets the plan's clinical criteria, and a well-prepared submission that directly addresses each criterion typically succeeds on first submission or on initial appeal.

## Your Appeal Rights

• Initial PA submission: The first step is a complete PA request submitted by your prescriber through Aetna's prior authorization portal or fax system. Confirm this was done before treating the situation as an appeal.
• ACA §2719 / ERISA §503: If the PA was denied, federal law entitles you to a full internal appeal and independent external review.
• Internal appeal deadline: Typically 180 days from the denial; check your Explanation of Benefits.
• External review window: Approximately four months from a final internal denial to request independent external review.
• Expedited PA and appeal: If your condition is urgent, both the initial PA review and any appeal can be requested on an expedited basis. State this explicitly in writing.

## Documentation to Gather

1. Diagnosis confirmation: Current chart notes clearly documenting your diagnosis, including severity indicators recorded in your medical record. 2. Prior treatment history with dates and outcomes: A complete chronology of every prior therapy — with start dates, stop dates, doses used (per the chart), and the specific clinical result — that Aetna's criteria may require as step therapy or prior failure evidence. 3. Clinical severity documentation: Objective clinical findings from your chart that reflect the severity of your condition and the clinical urgency of treatment. 4. Prescriber medical-necessity letter: A letter that mirrors Aetna's PA criteria point by point, confirming your case satisfies each requirement. Generic letters are frequently the reason PAs are denied; specificity is critical. 5. Insurer policy mapping: Obtain Aetna's current PA criteria document for tirzepatide. Address every listed requirement with a corresponding chart citation.

## Criteria-Mapping Structure

Before submitting, create a checklist from Aetna's published PA criteria: Criterion | Required evidence | Your chart evidence and source document. Give this table to your prescriber's office so they can confirm the submission is complete before it is filed. Incomplete submissions are the leading cause of PA denials that are entirely avoidable.

Verify the current PA criteria from Aetna's most recently published clinical policy and cross-check against the FDA-approved prescribing information before the submission is finalized.